Abstract: Disclosed are novel cross-linkable end-cappers for oligo-and polyimides. End-capped oligo-and polyimides comprising such an end-capper may be cured at a lower temperature compared to oligo-and polyimides end-capped with PEPA.

Abstract: This invention relates to novel substituted isoindoline-1,3-dione derivatives and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel substituted isoindoline-1,3-dione derivatives that are analogues of apremilast. This invention also provides compositions comprising a compound of this invention and a carrier and the use of disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering apremilast.

Abstract: This invention relates to novel substituted isoindoline-1,3-dione derivatives and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel substituted isoindoline-1,3-dione derivatives that are analogues of apremilast. This invention also provides compositions comprising a compound of this invention and a carrier and the use of disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering apremilast.

Abstract: Compounds having the general structure I are provided. X and Y are independently selected from the group consisting of CH2, N, NR9, C?O, C?S, S?O, SO2, S, O, (CR6R7)n, C(?O)—(CR6R7)n, and C(?S)—(CR6R7)n, where n is 1, 2, or 3. W is selected from the group consisting of (formula I) and L is selected from the group consisting of N, O, S?O, SO2, C(O), NC(O), NC(S), OC(O), OC(S), C(NR10), C(NOR10), and a covalent bond. Z1, Z2, and Z3 are independently selected from the group consisting of substituted carbon and nitrogen. Compounds of formula I are agonists of the melanocortin-4 receptor (“MC-4r2) and therefore may have useful properties for controlling diseases related to MC-4r action in humans, such as obesity and type II diabetes.

Abstract: Compounds of the formula I are suitable for preparing pharmaceuticals for the prophylaxis and therapy of disorders in whose course an increased activity of NF?B is involved.

Abstract: The invention relates to a novel class of aminobenzophenones derivatives, to pharmaceutical preparations comprising said compounds, to dosage units of such preparations, to methods of treating patients comprising administering said compounds, and to the use of said compounds in the manufacture of pharmaceutical preparations.

Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity.

Abstract: Novel compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism and obesity.

Abstract: Polymer encapsulated metal oxide particles are prepared by combining a polyamide acid in a polar aprotic solvent with a metal alkoxide solution. The polymer was imidized and the metal oxide formed simultaneously in a refluxing organic solvent. The resulting polymer-metal oxide is an intimately mixed commingled blend, possessing synergistic properties of both the polymer and preceramic metal oxide. The encapsulated metal oxide particles have multiple uses including, being useful in the production of skin lubricating creams, weather resistant paints, as a filler for paper, making ultraviolet light stable filled printing ink, being extruded into fibers or ribbons, and coatings for fibers used in the production of composite structural panels.

Abstract: Fluorinated imides useful for imparting repellency of low surface tension fluids to thermoplastic polymers of formulae ##STR1## wherein R.sub.1 is F(CF.sub.2).sub.x --(CH.sub.2).sub.m, or F(CF.sub.2).sub.x SO.sub.2 N(R.sub.5) (CH.sub.2)p wherein x is from about 4 to about 20, m is from about 2 to about 6, p is from 1 to about 12, and R.sub.5 is an alkyl radical of from 1 to about 4 carbons;R.sub.2 is a linear, branched or cyclic alkylene or poly(oxyalkylene) hydrocarbon group having from about 2 to about 15 carbons;R.sub.3 is selected from the group consisting of F(CF.sub.2).sub.x --(CH.sub.2).sub.m, F(CF.sub.2).sub.x --(CH.sub.2).sub.m --OC(O)--(CH.sub.2).sub.n, and F(CF.sub.2).sub.x SO.sub.2 N(R.sub.5)(CH.sub.2).sub.p OC(O)(CH.sub.2).sub.n wherein x is from about 4 to about 20, m is from about 2 to about 6, n is about 2 to about 12, p is from 1 to about 12, and R.sub.5 is an alkyl radical of from 1 to about 4 carbons;R.sub.4 is an alkyl or alkenyl group of from about 4 to about 20 carbons, andR.sub.

Abstract: The present invention relates to inhibition of angiogenesis and the treatment of diseases mediated by angiogenesis. Particularly, the invention relates to the inhibition of neovascularization and the treatment of cancer. The invention further relates to the use of cytochalasin derivatives for the inhibition of angiogenesis and the treatment of angiogenesis associated diseases. The invention also relates to new isoindolinone compounds, compositions containing them, and methods of inhibiting angiogenesis and treating angiogenesis associated diseases with the isoindolinone derivatives.

Abstract: Fluorinated imides useful for imparting repellency of low surface tension fluids to thermoplastic polymers of formulae ##STR1## wherein R.sub.1 is F(CF.sub.2).sub.x --(CH.sub.2).sub.m, or F(CF.sub.2).sub.x SO.sub.2 N(R.sub.5)(CH.sub.2)p wherein x is from about 4 to about 20, m is from about 2 to about 6, p is from 1 to about 12, and R.sub.5 is an alkyl radical of from 1 to about 4 carbons;R.sub.2 is a linear, branched or cyclic alkylene or poly(oxyalkylene) hydrocarbon group having from about 2 to about 15 carbons;R.sub.3 is selected from the group consisting of F(CF.sub.2).sub.x --(CH.sub.2).sub.m, F(CF.sub.2).sub.x --(CH.sub.2).sub.m --OC(O)--(CH.sub.2).sub.n, and F(CF.sub.2).sub.x SO.sub.2 N(R.sub.5)(CH.sub.2).sub.p OC(O)(CH.sub.2).sub.nwherein x is from about 4 to about 20, m is from about 2 to about 6, n is about 2 to about 12, p is from 1 to about 12, and R.sub.5 is an alkyl radical of from 1 to about 4 carbons;R.sub.4 is an alkyl or alkenyl group of from about 4 to about 20 carbons, andR.sub.

Abstract: A process for making bis(ether anhydrides) employs alkylamines having low melting temperatures thus allowing for novel intermediate process steps for preparing bis(ether anhydrides). The alkylamines have alkyl groups which contain at least three carbon atoms and have boiling temperatures in the range of 48.degree. to 250.degree. C. at atmospheric pressure. As a result of using these amines, liquid alkylamines now can be employed in the imidization process step. The N-alkyl nitrophthalimides prepared from the recovered imidization product according to this invention can now be purified using liquid/liquid extraction or vacuum distillation. The alkyl nitrophthalimides prepared according to this invention provide for displacement reactions which now can be run at a high solids level. Likewise, the exchange reaction can be run at a higher solids level, and thus achieves an efficiency level which is higher than conventional processes.

Abstract: Fluorinated imides useful for imparting repellency of low surface tension fluids to thermoplastic polymers of formulae ##STR1## wherein R.sub.1 is F(CF.sub.2).sub.x --(CH.sub.2).sub.m, or F(CF.sub.2).sub.x SO.sub.2 N(R.sub.5) (CH.sub.2) .sub.p wherein x is from about 4 to about 20, m is from about 2 to about 6, p is from 1 to about 12, and R.sub.5 is an alkyl radical of from 1 to about 4 carbons;R.sub.2 is a linear, branched or cyclic alkylene or poly(oxyalkylene) hydrocarbon group having from about 2 to about 15 carbons;R.sub.3 is selected from the group consisting of F(CF.sub.2).sub.x --(CH.sub.2).sub.m, F(CF.sub.2).sub.x --(CH.sub.2).sub.m --OC(O)--(CH.sub.2).sub.n, and F(CF.sub.2).sub.x SO.sub.2 N(R.sub.5)(CH.sub.2).sub.p OC(O)(CH.sub.2).sub.n wherein x is from about 4 to about 20, m is from about 2 to about 6, n is about 2 to about 12, p is from 1 to about 12, and R.sub.5 is an alkyl radical of from 1 to about 4 carbons;R.sub.4 is an alkyl or alkenyl group of from about 4 to about 20 carbons, andR.sub.

Abstract: Novel phosphinic acid-containing peptidyl compounds of formula I are found to be useful inhibitors of matrix metalloendoproteinase-mediated diseases including osteoarthritis, rheumatoid arthritis, septic arthritis, tumor invasion in certain cancers, periodontal disease, corneal ulceration, proteinuria, dystrophobic epidermolysis bullosa, and coronary thrombosis associated with atherosclerotic plaque rupture. These inhibitors may also be useful in preventing the pathological sequelae following a traumatic injury that could lead to permanent disability. These compounds may also have utility as a means for birth control by preventing ovulation or implantation.

Abstract: A class of novel 1H-indole-1-functional compounds is disclosed together with the use of such indole compounds for inhibiting sPLA.sub.2 mediated release of fatty acids for treatment of conditions such as septic shock. The compounds are 1H-indole-1-acetamides, 1H-indole-1-acetic acid hydrazides, and 1H-indole-1-glyoxylamides.

Abstract: New soft .beta.-adrenergic blocking agents, useful in the treatment or prevention of cardiovascular disorders and in the treatment of glaucoma, have the formula ##STR1## wherein n is an integer from 0 to 10; R is C.sub.6 -C.sub.12 cycloalkyl-C.sub.p H.sub.2p --, C.sub.6 -C.sub.18 polycycloalkyl-C.sub.p H.sub.2p --, C.sub.6 -C.sub.18 polycycloalkenyl-C.sub.p H.sub.2p -- or C.sub.6 -C.sub.12 cycloalkenyl-C.sub.p H.sub.2p -- (wherein p is 0, 1, 2 or 3), or together with the adjacent ##STR2## group represents a variety of other complex ester groupings; R.sub.1 is C.sub.1 -C.sub.7 alkyl; and Ar is a divalent radical containing at least one aromatic nucleus. The corresponding pharmaceutically acceptable acid addition salts are also described.

Abstract: The present invention relates to 4-amino-3-hydroxy-phthalimidine, an important intermediate for the synthesis of 3-substituted 5-quinoline-carboxylic acid amides, and a process for the preparation thereof.

Abstract: Novel 1-piperazinyl-2-butenes and -2-butynes, intermediates and processes for the preparation thereof, and methods of treating psychoses utilizing compounds or compositions thereof are disclosed.

Abstract: A method for preparing an aromatic ether bisimide is provided. The mixture obtained from reacting a substituted phthalimide with a metal salt of a hydroxy aromatic compound in a non-polar solvent is extracted with about 4% to about 6% by weight aqueous alkali hydroxide solution to remove the reaction's by-products and thus provide substantially pure aromatic ether bisimide. The method is particularly suitable for extracting aromatic ether bisimide by-products from a continuous process preparing aromatic ether bisimide.

Abstract: The present invention provides tertiary and secondary amine compounds of the formula ##STR1## and the pharmaceutically acceptable salts thereof which are antagonists for alpha-2 adrenoreceptors and which inhibit serotonin (5-hydroxytryptamine, 5-HT) uptake.

Abstract: The invention provides a series of novel heterocyclic amides of the formula I in which the group A; CRa can be --CRb.dbd.CRa--, --CHRb--CHRa-- or --N.dbd.CRa--, the amidic group Re.L can be Rd.X.CO.NH, Re.X.CS.NH or Re.NH.CO attached to position 4, 5 or 6 of the benzenoid moiety, z is an acid group selected from the group consisting of carboxy, an acylsulphonamide residue of the formula CO.NH.SO.sub.n Rg and a tetrazolyl residue of the formula II and the radicals Ra, Rb, Rc, Rd, Re, Rf, Rg, Rh, n, X, G.sup.1,Q and G.sup.2 have the meanings defined in the following specification.The compounds of formula I are leukotriene antagonists.

Abstract: A process for preparing N-alkyl substituted nitrophthalimide by the nitration of N-alkyl substituted phthalimide using only nitric acid, said nitric acid having a concentration of at least about 95%, and then recovering N-alkyl nitrophthalimide from the nitric acid solution.

Abstract: The invention relates primarily to quaternized polycyclic compounds having the formula ##STR1## wherein m is an integer having a value of from 1 to 4; R is alkylene having from 3 to 8 carbon atoms and is optionally substituted with C.sub.1 to C.sub.4 alkyl; R.sub.2 together with the quaternary nitrogen, forms a 5 to 14 membered heterocyclic ring, said ring containing from 1 to 2 hetero atoms selected from the group of nitrogen, sulfur and oxygen; R.sub.1 forms a double bond in the heterocyclic ring of the quaternized nitrogen or is alkyl, alkyleneoxyalkyl, alkylhydroxy, aryl, aralkyl, aralkenyl, alkaryl, alkylamidoalkyl and X.sup.- is a chloride, bromide or iodide anion. The invention also relates to the preparation and use of said quaternized polycyclic compounds.

Abstract: A method is provided for making oxybisphthalimides by heating an N-organonitrophthalimide in the presence of an aprotic organic solvent in an alkali metal carboxylate.

Abstract: A means for decomposing undesirable by-products formed during the nitration by nitric acid only of N--C.sub.1 to C.sub.8 alkyl phthalimides which comprises elevating the temperature of the reaction mix during or following nitration and an improved nitration process incorporating said means.

Abstract: Heterocyclic quaternary ammonium salts such as N,N-di-n-butylpiperidinium bromide are excellent phase transfer agents for the preparation of aromatic ethers, as by the reaction of the disodium salt of bisphenol A with 4-nitro-N-methylphthalimide.

Abstract: Bis-quaternary ammonium and phosphonium salts such as bis(tri-n-butyl)-1,6-hexylenediammonium dibromide are excellent phase transfer agents for the preparation of aromatic ether imides, as by the reaction of the disodium salt of bisphenol A with 4-nitro-N-methylphthalimide.

Abstract: The yield of aromatic ether imides prepared by reacting a substituted phthalimide (such as 4-nitro-N-methylphthalimide) with an alkali metal salt of a hydroxyaromatic compound (such as the disodium salt of bisphenol A) in the presence of a phase transfer catalyst is improved by conducting the reaction in o-dichlorobenzene as diluent. When the reaction mixture is subsequently extracted with water and/or aqueous alkali, o-dichlorobenzene can also be used in recovery of the phase transfer catalyst from the aqueous phase by extraction thereof. Such recovery is improved by dissolving a substantial amount of inorganic salt in the aqueous phase and by conducting the o-dichlorobenzene extraction at elevated temperatures.

Abstract: A method is provided for making aromatic ether imides in the substantial absence of a solvent. A mixture of at least one halo-substituted phthalimide and at least one anhydrous alkali metal phenoxide salt is heated at a temperature at least sufficient to convert the halo-substituted phthalimide to the molten state and below the temperature at which the alkali metal phenoxide is thermally unstable.